Literature DB >> 24135890

Modifiable cardiovascular risk factors in patients with ankylosing spondylitis.

Björn Sundström1, Gunnar Johansson, Ingegerd Johansson, Solveig Wållberg-Jonsson.   

Abstract

The aim of this study was to evaluate whether modifiable cardiovascular disease (CVD) risk factors, e.g. atherogenic blood lipids, hypertension and lifestyle-related factors such as smoking, diet and physical inactivity, differ among patients with ankylosing spondylitis (AS) in comparison to the general population. Eighty-eight patients diagnosed with AS were identified by analysis of the databases of a previous community intervention programme, the Västerbotten intervention programme. The patients were compared with 351 controls matched for age, sex and study period. These databases include the results of blood samples analysed for cholesterol, triglycerides and plasma glucose, as well as data on hypertension, height, weight, smoking and dietary habits and physical activity. No significant differences were found between patients and controls regarding hypertension, body mass index, physical activity, diet or smoking. Levels of serum triglycerides (p < 0.01) and cholesterol (p < 0.01) were significantly lower in the patient group. Among the patients, the level of triglycerides correlated inversely with the intake of total fat (r s = -0.25, p < 0.05), monounsaturated fats (r s = -0.29, p < 0.05) and positively correlated to the intake of carbohydrates (r s = 0.26, p < 0.05). These associations were not apparent among the controls. In the cohort of AS patients studied, no differences were found regarding the modifiable risk factors for CVD compared with the general population. Hence, the increased presence of CVD in patients with AS may be caused by other factors such as differences in metabolism and medication such as NSAID or the chronic low-grade inflammation present in the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24135890     DOI: 10.1007/s10067-013-2410-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Prevention of cardiovascular disease in Sweden: the Norsjö community intervention programme--motives, methods and intervention components.

Authors:  L Weinehall; G Hellsten; K Boman; G Hallmans
Journal:  Scand J Public Health Suppl       Date:  2001       Impact factor: 3.021

Review 2.  Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Sylvain Mathieu; Laure Gossec; Maxime Dougados; Martin Soubrier
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

3.  Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care.

Authors:  L Weinehall; C G Hallgren; G Westman; U Janlert; S Wall
Journal:  Scand J Prim Health Care       Date:  1998-09       Impact factor: 2.581

4.  Validation and calibration of food-frequency questionnaire measurements in the Northern Sweden Health and Disease cohort.

Authors:  Ingegerd Johansson; Göran Hallmans; Asa Wikman; Carine Biessy; Elio Riboli; Rudolf Kaaks
Journal:  Public Health Nutr       Date:  2002-06       Impact factor: 4.022

5.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

6.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors:  Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

7.  Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis.

Authors:  Ann Bremander; Ingemar F Petersson; Stefan Bergman; Martin Englund
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

8.  The Västerbotten Intervention Programme: background, design and implications.

Authors:  Margareta Norberg; Stig Wall; Kurt Boman; Lars Weinehall
Journal:  Glob Health Action       Date:  2010-03-22       Impact factor: 2.640

9.  Aortic root disease and valve disease associated with ankylosing spondylitis.

Authors:  C A Roldan; J Chavez; P W Wiest; C R Qualls; M H Crawford
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

10.  Spondyloarthritis: a strong predictor of early coronary artery bypass grafting.

Authors:  I Hollan; K Saatvedt; S M Almdahl; K Mikkelsen; R Moer; P Halvorsen; T Veel; O T Førre
Journal:  Scand J Rheumatol       Date:  2008 Jan-Feb       Impact factor: 3.641

View more
  5 in total

Review 1.  Relationship between diet and ankylosing spondylitis: A systematic review.

Authors:  Tatiana V Macfarlane; Hadeel M Abbood; Ejaz Pathan; Katy Gordon; Juliane Hinz; Gary J Macfarlane
Journal:  Eur J Rheumatol       Date:  2017-10-25

Review 2.  Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations.

Authors:  Anne Tournadre; Sylvain Mathieu; Martin Soubrier
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-09-05       Impact factor: 5.346

3.  Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation.

Authors:  Sjoerd C Heslinga; Inge A Van den Oever; Alper M Van Sijl; Mike J Peters; Irene E Van der Horst-Bruinsma; Yvo M Smulders; Michael T Nurmohamed
Journal:  BMC Musculoskelet Disord       Date:  2015-04-09       Impact factor: 2.362

4.  Relationship between diet, oxidative stress, and inflammation in ankylosing spondylitis.

Authors:  Kübra Tel Adıgüzel; Fatma Gül Yurdakul; Nilgün Seremet Kürklü; Evren Yaşar; Hatice Bodur
Journal:  Arch Rheumatol       Date:  2021-10-18       Impact factor: 1.007

5.  Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice.

Authors:  Rabia Agca; Yvo Smulders; Michael Nurmohamed
Journal:  Heart       Date:  2021-03-04       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.